October 31, 2025

Single-Injection Omvoh Option Simplifies Ulcerative Colitis Care

The FDA approved Eli Lilly’s interleukin-23p19 antagonist Omvoh (mirikizumab-mrkz) as a once-monthly single-injection maintenance option for adults with moderately to severely active ulcerative colitis.

Conexiant

October 29, 2025

FDA Pushes Faster, Cheaper Route for Biosimilar Approval

The FDA released new draft guidance to streamline biosimilar development.

Conexiant

October 29, 2025

H-1B Visa Changes: Who Pays the Price?

New fee structure could hit hardest where physicians are needed most.

Conexiant

October 22, 2025

Do GLP-1RAs Differ in Cardiometabolic Protection?

Researchers found that liraglutide and semaglutide offer similar cardiovascular and kidney benefits in type 2 diabetes.

Conexiant

October 20, 2025

FDA Okays First Oral GLP-1 for CV Risk

Novo Nordisk’s once-daily GLP-1 tablet reduced major adverse cardiovascular events in high-risk adults, including those without prior heart attack or stroke.

Conexiant

October 07, 2025

EASO Issues Obesity Pharmacotherapy Guidance

EASO framework guides obesity drug selection by weight loss effect and complication focus.

Conexiant

October 03, 2025

Court Upholds State's "Doctor" Title Ban

Federal judge rules nurse practitioners with doctorates cannot use “doctor/Dr.” in advertising or health care settings likely to make patients think they’re physicians. 

Conexiant

January 24, 2025

CRC Risk: Comparing BMI with Central Obesity Metrics

New evidence links central obesity measures to higher colorectal cancer risk compared to body mass index.

Conexiant

September 05, 2025

Ancillary Features Don’t Improve LI-RADS Accuracy

The study raises questions about whether ancillary features still warrant inclusion in liver imaging workflows.

Conexiant